MedPath

ADMA Biologics

ADMA Biologics logo
🇺🇸United States
Ownership
Public
Established
2004-01-01
Employees
624
Market Cap
$4B
Website
http://www.admabiologics.com

An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)

Phase 4
Recruiting
Conditions
Primary Immune Deficiency
Interventions
Biological: Asceniv™
First Posted Date
2021-10-07
Last Posted Date
2022-09-16
Lead Sponsor
ADMA Biologics, Inc.
Target Recruit Count
12
Registration Number
NCT05070455
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

🇺🇸

Immunoe Research Centers, Centennial, Colorado, United States

🇺🇸

University of Utah, Salt Lake City, Utah, United States

Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16

Phase 4
Completed
Conditions
Humoral Immune Response
Interventions
Biological: Bivigam
First Posted Date
2017-05-24
Last Posted Date
2023-02-01
Lead Sponsor
ADMA Biologics, Inc.
Target Recruit Count
16
Registration Number
NCT03164967
Locations
🇺🇸

IMMUNOe Research Centers, Centennial, Colorado, United States

🇺🇸

Ohio Clinical Research Associates, Mayfield Heights, Ohio, United States

🇺🇸

Allergy Associates of the Palm Beaches, North Palm Beach, Florida, United States

and more 5 locations

A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products

Active, not recruiting
Conditions
Primary Immune Deficiency Disorder
Interventions
Biological: Other
Biological: Bivigam
First Posted Date
2017-01-31
Last Posted Date
2023-02-01
Lead Sponsor
ADMA Biologics, Inc.
Target Recruit Count
200
Registration Number
NCT03037359
Locations
🇺🇸

Discovery Clinical Trials, Dallas, Texas, United States

🇺🇸

Lysosomal Rare Disorders Research & Treatment Center, Fairfax, Virginia, United States

🇺🇸

Allergy Asthma & Immunology Relief, Charlotte, North Carolina, United States

and more 14 locations

Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

Phase 3
Completed
Conditions
Primary Immune Deficiency Disorder
Interventions
Biological: RI-002
First Posted Date
2013-03-20
Last Posted Date
2016-10-05
Lead Sponsor
ADMA Biologics, Inc.
Target Recruit Count
59
Registration Number
NCT01814800
Locations
🇺🇸

Asthma & Immunology Associates, Omaha, Nebraska, United States

🇺🇸

Allergy Associates of the Palm Beaches, P.A., North Palm Beach, Florida, United States

🇺🇸

Family Allergy Center, PC, Atlanta, Georgia, United States

and more 6 locations

RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

Phase 2
Completed
Conditions
Upper Respiratory Tract Infection
Lower Respiratory Tract Infection
Interventions
Biological: RI-001
First Posted Date
2008-03-10
Last Posted Date
2013-04-24
Lead Sponsor
ADMA Biologics, Inc.
Target Recruit Count
21
Registration Number
NCT00632463
Locations
🇨🇦

Hospital for Sick Children, Toronto, Ontario, Canada

🇺🇸

All Children's Hospital, St. Petersburg, Florida, United States

🇺🇸

University of California San Francisco, San Francisco, California, United States

and more 16 locations

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Phase 3
Completed
Conditions
Primary Immune Deficiency Disorders (PIDD)
Interventions
Biological: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
First Posted Date
2007-10-03
Last Posted Date
2021-07-30
Lead Sponsor
ADMA Biologics, Inc.
Target Recruit Count
63
Registration Number
NCT00538915
Locations
🇺🇸

Women's and Children's Hospital of Buffalo, Buffalo, New York, United States

🇺🇸

University of Alabama, Birmingham, Alabama, United States

🇺🇸

1st Allergy and Clinical Resaerch center, Centennial, Colorado, United States

and more 14 locations

Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

Phase 2
Terminated
Conditions
Sequelae of Viral Hepatitis
Transplantation Infection
Evidence of Liver Transplantation
Interventions
Biological: Hepatitis C Immune Globulin Intravenous (Human) 5%
First Posted Date
2007-05-16
Last Posted Date
2021-07-30
Lead Sponsor
ADMA Biologics, Inc.
Target Recruit Count
7
Registration Number
NCT00473824
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath